Esperion CLO sells shares to cover RSU taxes

Rhea-AI Filing Summary

Esperion Therapeutics, Inc. Chief Legal Officer Benjamin Looker reported an open-market sale of 5,708 shares of common stock. The shares were sold at an average price of $2.703 per share to satisfy tax obligations on vested restricted stock units. After this transaction, he directly holds 679,348 shares, indicating that the sale represents a small portion of his overall position.

Insights

Equity compensation and insider-trading analyst

Small, tax-driven sale with minimal impact on overall insider stake.

Chief Legal Officer Benjamin Looker sold 5,708 shares of Esperion Therapeutics common stock at $2.703 per share. A footnote explains the sale was made to satisfy tax obligations related to vested restricted stock units, a common mechanism for handling equity-compensation taxes.

Following the sale, he still directly owns 679,348 shares, so the transaction is a small fraction of his disclosed holdings. Because the sale is tied to tax withholding rather than a discretionary position change, it carries limited signaling value about management’s view of the stock.

Insider Trade Summary

Net Seller: 5,708 shares

Net Sell 1 txn

Insider Looker Benjamin

Role Chief Legal Officer

Sold 5,708 shs ($15K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,708	$2.703	$15K

Holdings After Transaction: Common Stock — 679,348 shares (Direct)

Footnotes (1)

1. F1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

FAQ

What insider transaction did Esperion Therapeutics (ESPR) report for Benjamin Looker?

Esperion Therapeutics reported that Chief Legal Officer Benjamin Looker sold 5,708 shares of common stock. The shares were sold at an average price of $2.703 per share, according to a Form 4 insider filing with the SEC.

Why did Esperion Therapeutics (ESPR) executive Benjamin Looker sell shares?

The shares were sold to satisfy tax obligations on vested restricted stock units. This type of transaction is typically administrative, helping cover income taxes triggered when equity awards vest, rather than signaling a major change in the insider’s investment stance.

How many Esperion Therapeutics (ESPR) shares does Benjamin Looker hold after the sale?

After the reported sale, Chief Legal Officer Benjamin Looker directly owns 679,348 shares of Esperion Therapeutics common stock. This indicates the 5,708 shares sold represent a relatively small portion of his total disclosed holdings in the company.

Was the Esperion Therapeutics (ESPR) insider transaction an open-market sale?

Yes. The Form 4 categorizes the transaction as an open-market sale of common stock with transaction code “S.” However, a footnote clarifies the purpose was to cover tax obligations arising from vested restricted stock units, making it primarily a tax-related event.

Does the Esperion Therapeutics (ESPR) Form 4 show any option exercises or derivative trades?

No derivative securities or option exercises are listed in this Form 4. The filing shows only one non-derivative transaction: an open-market sale of 5,708 shares of common stock, undertaken to satisfy tax obligations on recently vested restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 04:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Looker Benjamin

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MICHIGAN 48108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S		5,708(1)	D	$2.703	679,348	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)